Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Varibar Pudding
Overview
What is Varibar Pudding?
VARIBAR PUDDING (barium sulfate) is a radiographic
contrast agent that is supplied as a 40 % w/v ready to use paste with
a vanilla aroma for oral administration. The active ingredient barium
sulfate is designated chemically as BaSO4 with a molecular weight
of 233.4 g/mol and the following chemical structure:
VARIBAR PUDDING has a
viscosity of 5000 cPs and contains the following excipients: artificial
vanilla flavor, carboxymethylcellulose sodium, citric acid, ethyl
vanillin, glycerin, maltodextrin, polysorbate 80, potassium sorbate,
purified water, saccharin sodium, simethicone emulsion, sodium benzoate,
xanthan gum, and xylitol.
What does Varibar Pudding look like?
What are the available doses of Varibar Pudding?
Oral paste: barium sulfate (40%
w/v) in a 230 mL multiple dose tube for oral administration ()
What should I talk to my health care provider before I take Varibar Pudding?
How should I use Varibar Pudding?
VARIBAR PUDDING is indicated for modified barium swallow examinations
to evaluate the oral and pharyngeal function and morphology in adult
and pediatric patients 6 months of age and older.
For oral use only – administered by syringe or spoon ()
Multiple doses may be administered
Maximum cumulative dose : 30 mL
What interacts with Varibar Pudding?
Sorry No Records found
What are the warnings of Varibar Pudding?
Sorry No Records found
What are the precautions of Varibar Pudding?
Sorry No Records found
What are the side effects of Varibar Pudding?
Sorry No records found
What should I look out for while using Varibar Pudding?
VARIBAR PUDDING is contraindicated in patients with:
- known or suspected perforation
of the gastrointestinal (GI) tract;- known obstruction
of the GI tract;- high risk of GI perforation such as
those with a recent GI perforation, acute GI hemorrhage or ischemia,
toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI
injury or burn, or recent radiotherapy to the pelvis;-
high risk for aspiration such as those with known or suspected tracheo-esophageal
fistula or obtundation;- known hypersensitivity to barium
sulfate or any of the excipients of VARIBAR PUDDING.
What might happen if I take too much Varibar Pudding?
Sorry No Records found
How should I store and handle Varibar Pudding?
One-vial formulation (Injection)Store between 15°C and 25°C (59°F and 77°F); Retain in the original package to protect from light. Freezing does not adversely affect the product.After initial puncture, Docetaxel Injection multiple dose vials are stable for 28 days when stored at room temperature, with protection from light.One-vial formulation (Injection)Store between 15°C and 25°C (59°F and 77°F); Retain in the original package to protect from light. Freezing does not adversely affect the product.After initial puncture, Docetaxel Injection multiple dose vials are stable for 28 days when stored at room temperature, with protection from light.One-vial formulation (Injection)Store between 15°C and 25°C (59°F and 77°F); Retain in the original package to protect from light. Freezing does not adversely affect the product.After initial puncture, Docetaxel Injection multiple dose vials are stable for 28 days when stored at room temperature, with protection from light.VARIBAR PUDDING is supplied as a paste in a multiple-dose polyethylene tube containing 230 mL of barium sulfate (40 % w/v).Provided as: 12 X 230 mL tubes (NDC 32909-125-22)Store at USP Controlled Room Temperature 20 to 25°C (68 to 77° F). Protect from freezing.Once opened, VARIBAR PUDDING may be used for up to 21 days when stored at USP Controlled Room Temperature, 20 to 25°C (68 to 77° F).VARIBAR PUDDING is supplied as a paste in a multiple-dose polyethylene tube containing 230 mL of barium sulfate (40 % w/v).Provided as: 12 X 230 mL tubes (NDC 32909-125-22)Store at USP Controlled Room Temperature 20 to 25°C (68 to 77° F). Protect from freezing.Once opened, VARIBAR PUDDING may be used for up to 21 days when stored at USP Controlled Room Temperature, 20 to 25°C (68 to 77° F).VARIBAR PUDDING is supplied as a paste in a multiple-dose polyethylene tube containing 230 mL of barium sulfate (40 % w/v).Provided as: 12 X 230 mL tubes (NDC 32909-125-22)Store at USP Controlled Room Temperature 20 to 25°C (68 to 77° F). Protect from freezing.Once opened, VARIBAR PUDDING may be used for up to 21 days when stored at USP Controlled Room Temperature, 20 to 25°C (68 to 77° F).VARIBAR PUDDING is supplied as a paste in a multiple-dose polyethylene tube containing 230 mL of barium sulfate (40 % w/v).Provided as: 12 X 230 mL tubes (NDC 32909-125-22)Store at USP Controlled Room Temperature 20 to 25°C (68 to 77° F). Protect from freezing.Once opened, VARIBAR PUDDING may be used for up to 21 days when stored at USP Controlled Room Temperature, 20 to 25°C (68 to 77° F).
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Due to its high atomic number, barium (the active ingredient
in VARIBAR PUDDING) is opaque to x-rays and therefore acts as a positive
contrast agent for radiographic studies.
Non-Clinical Toxicology
VARIBAR PUDDING is contraindicated in patients with:- known or suspected perforation of the gastrointestinal (GI) tract;- known obstruction of the GI tract;- high risk of GI perforation such as those with a recent GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to the pelvis;- high risk for aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation;- known hypersensitivity to barium sulfate or any of the excipients of VARIBAR PUDDING.
Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine.
Steady-state plasma digitoxin concentrations did not appear to change. Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens. The utilization of digitoxin for such patients may be considered as an alternative.
An interaction study between gentamicin and cytarabine showed a cytarabine related antagonism for the susceptibility of strains. This study suggests that in patients on cytarabine being treated with gentamicin for a infection, the lack of a prompt therapeutic response may indicate the need for re-evaluation of antibacterial therapy.
Clinical evidence in one patient showed possible inhibition of fluorocytosine efficacy during therapy with cytarabine injection. This may be due to potential competitive inhibition of its uptake.
Barium sulfate preparations contain a number of excipients, including natural and artificial flavors and may induce serious hypersensitivity reactions. The manifestations include: hypotension, bronchospasm and other respiratory impairments, and dermal reactions including rashes, urticaria, and itching. A history of bronchial asthma, atopy, food allergies, or a previous reaction to a contrast agent may increase the risk for hypersensitivity reactions. Emergency equipment and trained personnel should be immediately available for treatment of a hypersensitivity reaction.
The following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).